This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research Article
Mohammad Amin Karimi
Shahid Beheshti University of Medical Sciences
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Because of the high prevalence of cardiovascular diseases and their urgent treatment in a way that have minimal side effects and maximum benefits, this study aims to compare the mortality rate, re-hospitalization, and ejection fraction of smoker patients undergone P-PCI (primary percutaneous coronary intervention) with those who received thrombolytic therapy in autumn 2018.
Methods: This cross-sectional study was done in Ayatollah Taleghani and Labbafinejad hospitals of Tehran City, Iran. The study group consisted of 42 smoker patients referred to the hospitals with the diagnosis of ST-Elevation Myocardial Infarction (STEMI) and have undergone P-PCI or thrombolytic therapy from September 2018 to December 2018. Complications such as death and re-hospitalization were noted, and the ejection fraction of each patient was also recorded. Statistical analyses were performed using SPSS version 25. Statistical significance was considered at P< 0.05.
Results: The Independent Samples t-test showed no significant difference between two groups of PCI and thrombolytic therapy regarding ejection fraction (EF) at the time of admission. Also, there was no considerable EF difference after three months of follow-up between 2 groups in both smoker and ex-smoker ones (P>0.05). Mean (SD) values of EF in smoker patients who underwent PCI were 41.56 9.95 at the time of admission and 45.00 10.52 after three months of follow-up. The paired sample t-test showed no significant difference between both groups regarding EF at the time of admission and after three months. The mean (SD) values of EF in smoker patients who underwent thrombolytic therapy were 40.26 8.73 at the time of admission and 48.53 5.80 after three months of follow-up. The paired sample t-test showed no significant difference between EF at the time of admission and after three months in the ex-smoker group, but there was a considerable difference in the smoker group (P<0.05). Three months mortality rate was estimated at 23.1% in smokers with PCI and 7.1% in patients treated with thrombolytic therapy.
Conclusion: Thrombolytic therapy can increase the EF of smoking patients with STEMI for a long time, indicating a beneficial effect of thrombolytic therapy to prevent heart failure.
Keywords
Primary PCI, Thrombolytic therapy, Smoker patients' EF, STEMI
Figure 1
Figure 2
Figure 3
No competing interests reported.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 19 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiac & Cardiovascular Systems
Learn more about our company.
This is a preprint. It has not completed peer review.
Research Article
Mohammad Amin Karimi
Shahid Beheshti University of Medical Sciences
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 19 Mar, 2021
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cardiac & Cardiovascular Systems
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Because of the high prevalence of cardiovascular diseases and their urgent treatment in a way that have minimal side effects and maximum benefits, this study aims to compare the mortality rate, re-hospitalization, and ejection fraction of smoker patients undergone P-PCI (primary percutaneous coronary intervention) with those who received thrombolytic therapy in autumn 2018.
Methods: This cross-sectional study was done in Ayatollah Taleghani and Labbafinejad hospitals of Tehran City, Iran. The study group consisted of 42 smoker patients referred to the hospitals with the diagnosis of ST-Elevation Myocardial Infarction (STEMI) and have undergone P-PCI or thrombolytic therapy from September 2018 to December 2018. Complications such as death and re-hospitalization were noted, and the ejection fraction of each patient was also recorded. Statistical analyses were performed using SPSS version 25. Statistical significance was considered at P< 0.05.
Results: The Independent Samples t-test showed no significant difference between two groups of PCI and thrombolytic therapy regarding ejection fraction (EF) at the time of admission. Also, there was no considerable EF difference after three months of follow-up between 2 groups in both smoker and ex-smoker ones (P>0.05). Mean (SD) values of EF in smoker patients who underwent PCI were 41.56 9.95 at the time of admission and 45.00 10.52 after three months of follow-up. The paired sample t-test showed no significant difference between both groups regarding EF at the time of admission and after three months. The mean (SD) values of EF in smoker patients who underwent thrombolytic therapy were 40.26 8.73 at the time of admission and 48.53 5.80 after three months of follow-up. The paired sample t-test showed no significant difference between EF at the time of admission and after three months in the ex-smoker group, but there was a considerable difference in the smoker group (P<0.05). Three months mortality rate was estimated at 23.1% in smokers with PCI and 7.1% in patients treated with thrombolytic therapy.
Conclusion: Thrombolytic therapy can increase the EF of smoking patients with STEMI for a long time, indicating a beneficial effect of thrombolytic therapy to prevent heart failure.
Figure 1
Figure 2
Figure 3
Loading...